StockData

Vyome vs Kazia Therapeutics

HIND and KZIA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HIND and KZIA compare

Vyome grew revenue faster over the last twelve months (−67.1% versus −98.2% for Kazia Therapeutics).

Vyome keeps more of each dollar of sales as profit, with a net margin of −8717% compared with −49291% at Kazia Therapeutics.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHINDKZIA
Size and price
Market cap$10.8M–
Share price$1.54$5.31
Change, 1 year−68.3%−15.3%
Change, 5 years−100.0%−98.9%
Beta (5Y)1.604.08
Employees1814
StockData Score
Total score11
Valuation score00
Growth score00
Performance score00
Health score11
Dividend score00
Valuation
P/S83.6×–
Growth
Revenue growth (TTM)−67.1% (better)−98.2%
Revenue growth, 5Y average−51.0%–
Profitability
Gross margin52.7%–
Operating margin−9190%–
Net margin−8717% (better)−49291%
Return on equity−194%–
Return on invested capital−173%–
Financial health
Interest coverage−285.8×–
Current ratio4.37 (better)2.87
Altman Z-score−13.57–
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield39.6%–
Shareholder yield39.6%–
Ownership
Held by institutions2.0%0.45%
Held by insiders6.8%0.29%
Superinvestors holding–1
Short interest, % of float0.28%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.